Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
ConditionSchizophrenia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBristol-Myers Squibb
About this trial
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Eligibility criteria
Qualifiers
Aged ≥18 years at index date.
Have a confirmed diagnosis of schizophrenia before index date.
Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy.
Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines.
Disqualifiers
Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening.
Evidence of use of XT prior to time of eligibility screening.
Trial design
Treatments tested in this trial
- xanomeline and trospium chloride (X/T) therapy
Treatment groups
300 Participants
are divided into 1 treatment groupLocations
18California
Local Institution - 000992868, Orange United States
Lumos Clinical Research Center95124, San Jose United States
Illinois
Local Institution - 000360201, Evanston United States
Maryland
The Johns Hopkins Hospital21287, Baltimore United States
Sponsors and collaborators
Bristol-Myers Squibb
Lead sponsor
Source ClinicalTrials.gov